Coronary artery stents. Appropriate use of adjunctive pharmacotherapy to prevent stent thrombosis

Drugs and Aging

Volumn 15, Issue 5, 1999, Pages 341-348

  Gruberg, Luis ^a   Dangas, George ^a,b   Leon, Martin B ^a  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DEXTRAN; DEXTRAN 40; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PHENPROCOUMON; TICLOPIDINE; WARFARIN;

AGRANULOCYTOSIS; ANTICOAGULANT THERAPY; BLEEDING; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DRUG BIOAVAILABILITY; DRUG COST; DRUG HALF LIFE; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; ORAL DRUG ADMINISTRATION; PANCYTOPENIA; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PEROPERATIVE ECHOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE ACTIVATION;

ADJUVANTS, PHARMACEUTIC; ANTICOAGULANTS; CLINICAL TRIALS; CORONARY DISEASE; CORONARY THROMBOSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS;

EID: 0032728186     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199915050-00002     Document Type: Review

References (42)

1. 1. Dotter CT, Buschmann RW, McKinney MK, et al. Transluminal expandable nitinol coil stent grafting: preliminary report. Radiology 1983; 147: 259-60
2. 2. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 326: 701-6
3. 3. Pepine CJ, Holmes DR. Coronary stents: ACC expert consensus document. J Am Coll Cardiol 1996; 28: 782-94
4. 4. Popma JJ, Coller BS, Ohman EM, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1995; Suppl. 108: 486S-501
5. 5. Steinhubl SR, Lincoff MA. Antithrombotic therapy with intracoronary stenting. Heart 1997; 78 Suppl. 2: 21-3
6. 6. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501
7. 7. Scrruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-95
8. 8. Mak K-H, Belli G, Ellis SG, et al. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol 1996; 27: 494-503
9. 9. Bittl JA. Coronary stent occlusion: thrombus horribilis. J Am Coll Cardiol 1996; 28: 368-70
10. 10. Neumann F-J, Gawaz M, Ott I, et al. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 1996; 27: 15-21
11. 11. Eitzmann DT, Chi L, Saggin L, et al. Heparin neutralization by platelet rich thrombi: role of platelet factor 4. Circulation 1994; 89: 1523-9
12. 12. Hasdai D, Garratt KN, Holmes DR, et al. Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. J Am Coll Cardiol 1996; 28: 361-7
13. 13. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-9
14. 14. Theroux P. Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin? Am Heart J 1997; 134: S62-70
15. 15. Matthiasson SE, Lindblad B, Bergvist D. Prevention of experimental venous thrombosis in rabbits with low molecular weight heparin, dextran, and their combinations, administered before or during induction of venous endothelial trauma. Thromb Res 1994; 74: 655-63
16. 16. Gossman DE, Schneider F. Hapten resistant dextran induced ARDS reaction following intracoronary stent deployment. Cathet Cardiovasc Diagn 1996; 38: 56-61
17. 17. Morice MC, Zemour G, Bemveniste E, et al. Intracoronary stenting without coumadin: one month results of a French multicenter study. Cathet Cardiovasc Diagn 1995; 35: 1-7
18. 18. Fernandez-Aviles F, Alonso JJ, Duran JM, et al. Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen. J Am Coll Cardiol 1996; 27: 22-9
19. 19. Goldberg SL, Colombo A, Nakamura S, et al. Benefit of intracoronary ultrasound in the deployment of Palmaz-Schatz stents. J Am Coll Cardiol 1994; 24: 996-1003
20. 20. Nakamura S, Colombo A, Gaglione S, et al. Intracoronary ultrasound observations during stent implantation. Circulation 1994; 89: 2026-34
21. 21. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91: 1676-88
22. 22. Karillon G, Morice MC, Benveniste E, et al. Intravascular stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French multicenter registry. Circulation 1996; 94: 1519-27
23. 23. Morice MC, Valeix B, Marco J, et al. Preliminary results of the MUST Trial: major clinical events during the first month. J Am Coll Cardiol 1996; 27 Suppl. A: 137A
24. 24. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394-405
25. 25. Defreyn G, Bernat A, Delebassee D, et al. Pharmacology of ticlopidine: a review. Semin Thromb Hemost 1989; 15: 159-66
26. 26. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998; 339: 1665-71
27. 27. Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334 (17): 1084-9
28. 28. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996; 93: 215-22
29. 29. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the full anticoagulation versus aspirin and ticlopidine (FANTASTIC) Study. Circulation 1998; 98: 1597-603
30. 30. Urban P, Macaya C, Rupprecht H-J, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high risk-patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98: 2126-32
31. 31. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998; 128: 541-4
32. 32. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA 1999; 281: 806-10
33. 33. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel vs aspirin in patients at risk for ischemic events (CAPRIE). Lancet 1996; 348: 1329-39
34. 34. Berger PB, Bellot V, Melby S, et al. Clopidogrel versus ticlopidine for coronary stents: For the Cardiac Catheterization Laboratory. J Am Coll Cardiol 1999; 33 Suppl. A: 34A
35. 35. Berger PB. Aspirin, ticlopidine and clopidogrel in and out of the catheterization laboratory. J Invasive Cardiol 1999; 11 Suppl. A: 20A-9
36. 36. Mishkel GJ, Lucore CL, Ligon RW, et al. Clopidogrel for the prevention of stent thrombosis. J Am Coll Cardiol 1999; 33 Suppl. A: 34A
37. 37. Coller BS. Platelet GP IIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997; 99: 1467-71
38. 38. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92
39. 39. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349: 1422-8
40. 40. Kerciakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997; 96: 1117-21
41. 41. Steinhubl SR, Lauer MS, Mukherjee DP, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarction. J Am Coll Cardiol 1998; 32: 1366-70
42. 42. Lincoff AM, Tcheng J, Califf RM, et al. Standard versus low-dose weight adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3Fab) during percutaneous coronary revascularization. Am J Cardiol 1997; 79: 286-91